Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Operating Leases (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Operating Leases for 5 consecutive years, with $4.2 million as the latest value for Q2 2025.

  • Quarterly Operating Leases changed 0.0% to $4.2 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Jun 2025, changed 0.0% year-over-year, with the annual reading at $2.3 million for FY2024, 60.25% down from the prior year.
  • Operating Leases hit $4.2 million in Q2 2025 for Kezar Life Sciences, up from $1.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $8.9 million in Q4 2022 to a low of $1.4 million in Q1 2025.
  • Historically, Operating Leases has averaged $4.4 million across 5 years, with a median of $4.0 million in 2021.
  • Biggest five-year swings in Operating Leases: surged 201.31% in 2023 and later tumbled 73.02% in 2025.
  • Year by year, Operating Leases stood at $3.2 million in 2021, then skyrocketed by 175.05% to $8.9 million in 2022, then tumbled by 33.99% to $5.9 million in 2023, then tumbled by 60.25% to $2.3 million in 2024, then skyrocketed by 78.5% to $4.2 million in 2025.
  • Business Quant data shows Operating Leases for KZR at $4.2 million in Q2 2025, $1.4 million in Q1 2025, and $2.3 million in Q4 2024.